Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dominant T-cell Receptor Delta Rearrangements in B-cell Precursor Acute Lymphoblastic Leukemia: Leukemic Markers or Physiological γδ T Repertoire?
Kelm M, Darzentas F, Darzentas N, Kotrova M, Wessels W, Bendig S, Baldus CD, Lettau M, Gökbuget N, Kabelitz D, Brüggemann M, Chitadze G. Kelm M, et al. Among authors: bruggemann m. Hemasphere. 2023 Sep 1;7(9):e948. doi: 10.1097/HS9.0000000000000948. eCollection 2023 Sep. Hemasphere. 2023. PMID: 37670805 Free PMC article. No abstract available.
Risk-adapted treatment according to minimal residual disease in adult ALL.
Gökbuget N, Kneba M, Raff T, Bruggemann M, Scheuring U, Reutzel R, Hoelzer D. Gökbuget N, et al. Among authors: bruggemann m. Best Pract Res Clin Haematol. 2002 Dec;15(4):639-52. doi: 10.1053/beha.2002.0229. Best Pract Res Clin Haematol. 2002. PMID: 12617868 Review.
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.
Brüggemann M, Raff T, Flohr T, Gökbuget N, Nakao M, Droese J, Lüschen S, Pott C, Ritgen M, Scheuring U, Horst HA, Thiel E, Hoelzer D, Bartram CR, Kneba M; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Brüggemann M, et al. Blood. 2006 Feb 1;107(3):1116-23. doi: 10.1182/blood-2005-07-2708. Epub 2005 Sep 29. Blood. 2006. PMID: 16195338 Free article. Clinical Trial.
Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials.
Raff T, Gökbuget N, Lüschen S, Reutzel R, Ritgen M, Irmer S, Böttcher S, Horst HA, Kneba M, Hoelzer D, Brüggemann M; GMALL Study Group. Raff T, et al. Among authors: bruggemann m. Blood. 2007 Feb 1;109(3):910-5. doi: 10.1182/blood-2006-07-037093. Epub 2006 Oct 5. Blood. 2007. PMID: 17023577 Free article. Clinical Trial.
High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
Gökbuget N, Basara N, Baurmann H, Beck J, Brüggemann M, Diedrich H, Güldenzoph B, Hartung G, Horst HA, Hüttmann A, Kobbe G, Naumann R, Ratei R, Reichle A, Serve H, Stelljes M, Viardot A, Wattad M, Hoelzer D. Gökbuget N, et al. Among authors: bruggemann m. Blood. 2011 Sep 29;118(13):3504-11. doi: 10.1182/blood-2011-01-329441. Epub 2011 Jun 28. Blood. 2011. PMID: 21715318 Free article. Clinical Trial.
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.
Gökbuget N, Kneba M, Raff T, Trautmann H, Bartram CR, Arnold R, Fietkau R, Freund M, Ganser A, Ludwig WD, Maschmeyer G, Rieder H, Schwartz S, Serve H, Thiel E, Brüggemann M, Hoelzer D; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Gökbuget N, et al. Among authors: bruggemann m. Blood. 2012 Aug 30;120(9):1868-76. doi: 10.1182/blood-2011-09-377713. Epub 2012 Mar 22. Blood. 2012. PMID: 22442346 Free article. Clinical Trial.
Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations.
Neumann M, Heesch S, Schlee C, Schwartz S, Gökbuget N, Hoelzer D, Konstandin NP, Ksienzyk B, Vosberg S, Graf A, Krebs S, Blum H, Raff T, Brüggemann M, Hofmann WK, Hecht J, Bohlander SK, Greif PA, Baldus CD. Neumann M, et al. Among authors: bruggemann m. Blood. 2013 Jun 6;121(23):4749-52. doi: 10.1182/blood-2012-11-465138. Epub 2013 Apr 19. Blood. 2013. PMID: 23603912 Free article.
Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia.
Terwey TH, Hemmati PG, Nagy M, Pfeifer H, Gökbuget N, Brüggemann M, Le Duc TM, le Coutre P, Dörken B, Arnold R. Terwey TH, et al. Among authors: bruggemann m. Biol Blood Marrow Transplant. 2014 Oct;20(10):1522-9. doi: 10.1016/j.bbmt.2014.05.026. Epub 2014 Jun 4. Biol Blood Marrow Transplant. 2014. PMID: 24907626 Free article.
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
Topp MS, Gökbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, Viardot A, Marks R, Diedrich H, Faul C, Reichle A, Horst HA, Brüggemann M, Wessiepe D, Holland C, Alekar S, Mergen N, Einsele H, Hoelzer D, Bargou RC. Topp MS, et al. Among authors: bruggemann m. J Clin Oncol. 2014 Dec 20;32(36):4134-40. doi: 10.1200/JCO.2014.56.3247. Epub 2014 Nov 10. J Clin Oncol. 2014. PMID: 25385737 Clinical Trial.
284 results